Literature DB >> 31554247

Enantioselective 5-exo-Fluorocyclization of Ene-Oximes.

Taiki Rouno1, Tomoki Niwa2, Kousuke Nishibashi3, Nobuharu Yamamoto4, Hiromichi Egami5, Yoshitaka Hamashima6.   

Abstract

The enantioselective 5-exo-fluorocyclization of ene-oxime compounds was demonstrated under phase-transfer catalysis. Although deprotonative fluorinations competed, the chemical yields and the ee values of the desired isoxazoline products were generally moderate to good. The absolute stereochemistry of the major isomer was determined to be S by comparison with the literature after transformation of the product to the corresponding iodinated isoxazoline.

Entities:  

Keywords:  asymmetric catalysis; fluorine; oxime; phase-transfer catalysis

Year:  2019        PMID: 31554247      PMCID: PMC6804199          DOI: 10.3390/molecules24193464

Source DB:  PubMed          Journal:  Molecules        ISSN: 1420-3049            Impact factor:   4.411


1. Introduction

Isoxazoline framework has been recognized as a significant substructure of natural and unnatural compounds [1,2], which possess various biological activities including anticancer activity [3,4], FXa inhibitory activity [5], and antiparasitic activity [6,7,8,9]. Therefore, the construction of isoxazoline has been actively studied [10,11,12,13]. Among various methods for isoxazoline synthesis, a difunctionalization-type cyclization of ene-oxime is one of the major strategies. Cyclization reactions with concomitant introduction of a fluoroalkyl group [14,15,16,17], a hydroxyl group [18,19], a thiocyanate group [20], and an iodine group [21] have been reported so far. Fluorine chemistry has contributed to pharmaceutical and agrochemical sciences, because an introduction of fluorine atom(s) at an appropriate position often improves the property of the parent compounds in terms of metabolic stability, lipophilicity, and so on [22,23,24,25,26,27]. Thus, a tremendous amount of fluorination reactions, including the asymmetric versions have been investigated [28,29,30]. Reflecting that alkene is a useful feedstock in organic chemistry and easy to prepare, asymmetric fluoro-functionalizations of alkenes have attracted increasing attention [31,32,33,34,35,36,37]. However, there is no report of the asymmetric fluorocyclization of ene-oximes, while its racemic version was recently reported in 2017 [38]. Our recent research interests include the asymmetric fluorofunctionalization of alkenes by phase-transfer catalysis. In 2015, we reported the first successful example of asymmetric fluorolactonization of ene-carboxylic acids using a hydroxymethyl carboxylate phase-transfer catalyst [39]. Based on this study, we recently developed a linked-binaphthyl dicarboxylic acid precatalyst 1, which was proven to be highly effective for the asymmetric fluorocyclization and the deprotonative fluorination of allylic amides (Scheme 1a) [40,41]. In these reactions, hydrogen bonding between the catalyst and the substrate was considered to be crucial for high asymmetric induction. Considering pKa values of amide and oxime, we anticipated that oxime could interact with our anionic phase-transfer catalyst through hydrogen bonds, which would define the conformation of the substrate and/or a fluorinated carbocation intermediate. Our previous study suggested that the fluorocyclization of alkenes proceeds via the formation of a fluoro-carbocation intermediate [40,41]. If this is the case, hydrogen bond interaction of the cationic intermediate with the catalyst seems essential, because the intramolecular cyclization step is an enantio-determining step. Herein, we report our effort to develop the enantioselective 5-exo-fluorocyclization of ene-oximes to provide fluorinated isoxazolines (Scheme 1b).
Scheme 1

Fluorofunctionalizations of alkenes with linked-binaphthyl dicarboxylic acid 1 and Selectfluor: (a) Asymmetric 6-endo-type fluorocyclization of allylic amides; (b) Asymmetric 5-exo-fluorocyclization of ene-oximes.

2. Results and Discussion

Ene-oxime 2a [21] was chosen as a test substrate to optimize the reaction conditions (Table 1). At first, the reaction was carried out with 1 under the previous cyclization conditions [40] and the desired product, 3a, was obtained with 58% ee (entry 1). In this reaction, undesired byproducts were simultaneously observed by 1H NMR analysis of the crude mixture. Although these byproducts could not be purified at this point, 1H and 19F NMR analyses suggested that the byproducts were deprotonative fluorination products 4a–6a. The enantioselectivity observed in chlorobenzene and benzene was almost the same with that in toluene, but the reaction rate became somewhat slower (entries 1–3). Use of CH2Cl2 and THF resulted in low chemical yield (entries 4 and 5). While Na2SO4 had a positive effect in improving the chemical yield in our previous case [40,41], it did not affect the reaction efficiency in the present reaction (entries 1 and 6). Among bases tested, Na3PO4 was found to be the base of choice in terms of the chemical yield of the desired product 3a (entries 6–11). The enantioselectivity was almost similar (59%–61%), irrespective of the basicity and counter cation. Proton sponge provided a low yield and a low enantioselectivity under the described conditions (entry 11). As seen in entry 12, the reaction rate became slower at 15 °C, but a better enantioselectivity was observed (69% ee). In all cases, the yields based on the recovered starting material were around 65%. Interestingly, the ee of 6a was as high as 77% under the optimized conditions (entry 12), albeit in only 4% yield. It should be noted that phosphoric acid 7, which is a commonly used precursor of anionic phase transfer catalysts [33], did not promote the present reaction (entry 14), confirming the better performance of our dicarboxylate catalyst.
Table 1

Optimization of the reaction conditions. 1

EntryPrecatalystSolventBaseYield (%) 2Ee (%) 3
1 4 1 tolueneNa3PO43958
2 4 1 chlorobenzeneNa3PO42658
3 4 1 benzeneNa3PO43057
4 4 1 CH2Cl2Na3PO411-
5 4 1 THFNa3PO43-
6 1 tolueneNa3PO44259
7 1 tolueneNa2HPO41961
8 1 tolueneNa2CO33561
9 1 tolueneK3PO42459
10 1 tolueneK2CO33-
11 1 tolueneproton sponge177
12 5 1 tolueneNa3PO463 (58) 669
13 5 1 tolueneNa2CO362 (58) 665
14 5 7 tolueneNa3PO42-

1 The reactions were carried out with 2a (0.1 mmol), precatalyst (10 mol %), Selectfluor (1.5 equiv), and base (1.5 equiv) at 25 °C, unless otherwise mentioned. 2 The yields were determined by 1H NMR analysis using 1,1,2,2-tetrabromoethane as an internal standard. 3 The ee values were determined by HPLC analysis using a chiral stationary column. 4 Run with Na2SO4. 5 Run at 15 °C for 72 h. 6 Isolated yield.

To determine the absolute stereochemistry of the major isomer, the fluorinated isoxazoline 3a was transformed to the corresponding iodinated isoxazoline 8a with MgI2 using a sealed tube at 80 °C [42] (Scheme 2). Although the conversion was modest, 8a could be obtained without erosion of the ee value. The stereochemistry of the major isomer was determined to be S by comparing the retention time of HPLC analysis with that reported in the literature [21]. This result indicates that the major isomer of the present fluorocyclization is S.
Scheme 2

Conversion of 3a to 8a to determine the stereochemistry of the major product.

Having optimized the reaction conditions, other ene-oximes were transformed to the corresponding fluorinated isoxazolines (Figure 1). Reactions of para- and meta-methylated substrates proceeded to give the corresponding isoxazoline products with good ee values (3b, 3c). However, ortho-substituent retarded the reaction completely, probably due to the steric repulsion (3d). meta-Chlorinated and para-fluorinated isoxazolines were formed with 77% ee and 73% ee, respectively (3e and 3f). An ene-oxime bearing a cyclohexyl group was less reactive for the fluorocyclization and 3g was obtained in only 12% yield, even at room temperature. The chemical structure on the oxime side did not have a significant impact on the enantioselectivity (3h and 3i). To our delight, a substrate having a thiophen group provided 3j in 69% with 84% ee. We additionally performed the SDE (self-disproportionation of enantiomer) test by achiral column chromatography [43]. The difference between the first and the last fractions was less than 1% ee, suggesting that SDE did not occur. As usual, all fractions were collected after the chromatographic purification.
Figure 1

Fluorocyclization of ene-oximes.

To confirm the importance of hydrogen bond interaction between the oxime and the dianionic catalyst 1, the following control experiment was carried out. Thus, when O-methylated compound 9 was subjected to the described reaction conditions, no reaction occurred at all and the starting material 9 was just recovered (Scheme 3). Since even deprotonated products were not formed, it is likely that the hydrogen bond interaction has an important role in accelerating the fluorination step, in addition to the enantioselectivity control.
Scheme 3

Reaction of O-methylated compound.

3. Materials and Methods

3.1. General Information

1H and 19F NMR spectra were measured on a JEOL ECX-500 spectrometer at 500 and 470 MHz, respectively. 13C NMR spectra were recorded on a JEOL JNM-ECX-500 spectrometer at 125 MHz. Chemical shifts were reported in parts per million (ppm) downfield from TMS (δ = 0) for 1H NMR. For 13C NMR, chemical shifts were reported in the scale relative to CDCl3. For 19F NMR, chemical shifts were reported in a scale relative to CFCl3 external standard (δ = 0 ppm). Column chromatography was performed with silica gel N-60 (40–100 μm) purchased from Kanto Chemical Co., Inc. TLC analysis was performed on Silica gel 60 F254-coated glass plates (Merck). Visualization was accomplished by means of ultraviolet (UV) irradiation at 254 nm or by spraying an ethanol solution of 12-molybdo(VI)phosphoric acid as a developing agent. Dehydrated dichloromethane (CH2Cl2) and toluene were purchased from Wako Pure Chemical Industries, Ltd. Dehydrated tetrahydrofuran (THF), diethyl ether (Et2O), and benzene were purchased from Kanto Chemical Co., Inc. Selectfluor was purchased from Aldrich. Other reagents were purified by usual methods. The substrates were synthesized according to the literature [21]. The catalysts were synthesized according to the literature [40]. The 1H, 13C and 19F NMR spectra and HPLC data of compounds 3 are available in the Supplementary Material.

3.2. Asymmetric Fluorocyclization of Ene-Oximes

To a solution of 2a (23.7 mg, 0.1 mmol), 1 (9.7 mg, 10 mol %), and Na3PO4 (24.6 mg, 1.5 equiv) in toluene (1 mL), was added Selectfluor (53.1 mg, 1.5 equiv) at 15 °C under Ar atmosphere. After stirring for 72 h at 15 °C, the reaction mixture was diluted with EtOAc and filtrated through a pad of Celite. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography on silica gel (n-hexane/ethyl acetate = 20/1 → 15/1 → 10/1) to provide 3a as a colorless solid (14.8 mg, 58%). The ee value was determined by chiral HPLC analysis. 5-(Fluoromethyl)-3,5-diphenylisoxazoline (3a). Colorless solid (58%, 14.8 mg). [α]27D = 29.7 (c = 0.47, CHCl3). The ee value (69% ee) was determined by HPLC analysis using a chiralpack IG-3 (n-hexane/i-PrOH = 80:20, flow rate = 1.0 mL/min, t(minor) = 11.4 min, t(major) = 20.6 min). 1H NMR (500 MHz, CDCl3) δ = 7.69–7.67 (m, 2H), 7.53–7.51 (m, 2H), 7.43–7.38 (m, 5H), 7.36–7.33 (m, 1H), 4.64 (dd, J = 9.7, 47.5 Hz, 1H), 4.60 (dd, J = 9.7, 47.5 Hz, 1H), 3.89 (d, J = 16.6 Hz, 1H), 3.53 (dd, J = 2.3, 16.6 Hz, 1H). 13C NMR (125 MHz, CDCl3) δ = 156.2, 140.1 (d, J = 3.6 Hz), 130.3, 129.3, 128.7, 128.7, 128.4, 126.7, 125.5, 88.9 (d, J = 18.0 Hz), 85.5 (d, J = 183.5 Hz), 42.9 (d, J = 3.6 Hz). 19F NMR (470 MHz, CDCl3) δ = −221.3 (t, J = 47.5 Hz, 1F). IR (neat): 2941, 1599, 1447, 1362, 1020, 980, 912 cm−1. HRMS (ESI) m/z calcd. for C16H15FNO [M + H+]: 256.1132, found: 256.1131. 5-(Fluoromethyl)-3-phenyl-5-(p-tolyl)isoxazoline (3b). Colorless solid (46%, 12.7 mg). [α]29D = 31.8 (c = 0.38, CHCl3). The ee value (47% ee) was determined by HPLC analysis using a chiralpack IG-3 (n-hexane/i-PrOH = 80:20, flow rate = 1.0 mL/min, t(minor) = 13.4 min, t(major) = 23.5 min). 1H NMR (500 MHz, CDCl3) δ = 7.67–7.66 (m, 2H), 7.42–7.37 (m, 5H), 7.21 (d, J = 8.0 Hz, 2H), 4.61 (dd, J = 10.0, 47.4 Hz, 1H), 4.57 (dd, J = 10.0, 47.4 Hz, 1H) 3.86 (d, J = 16.6 Hz, 1H), 3.51 (dd, J = 1.7, 16.6 Hz, 1H), 2.35 (s, 3H). 13C NMR (125 MHz, CDCl3) δ = 156.2, 138.2, 137.1 (d, J = 3.6 Hz), 130.2, 129.4, 129.3, 128.7, 126.6, 125.4, 88.9 (d, J = 18.0 Hz), 85.5 (d, J = 183.5 Hz), 42.8 (d, J = 3.6 Hz), 21.0. 19F NMR (470 MHz, CDCl3) δ = −220.9 (t, J = 47.4 Hz, 1F). IR (neat): 2922, 1570, 1514, 1447, 1358, 978, 906 cm−1. HRMS (ESI) m/z calcd. for C17H17FNO [M + H+]: 270.1289, found: 270.1287. 5-(Fluoromethyl)-3-phenyl-5-(m-tolyl)isoxazoline (3c). Colorless solid (48%, 12.9 mg). [α]28D = 21.4 (c = 0.50, CHCl3). The ee value (54% ee) was determined by HPLC analysis using a chiralpack IG-3 (n-hexane/i-PrOH = 80:20, flow rate = 1.0 mL/min, t(minor) = 8.7 min, t(major) = 12.4 min). 1H NMR (500 MHz, CDCl3) δ = 7.69–7.68 (m, 2H), 7.41–7.39 (m, 3H), 7.35 (s, 1H), 7.30–7.29 (m, 2H), 7.17-7.15 (m, 1H), 4.63 (dd, J = 10.0, 47.6 Hz, 1H), 4.60 (dd, J = 10.0, 47.6 Hz, 1H), 3.88 (d, J = 16.6 Hz, 1H), 3.53 (dd, J = 2.3, 16.6 Hz, 1H), 2.39 (s, 3H). 13C NMR (125 MHz, CDCl3) δ = 156.2, 140.0 (d, J = 3.6 Hz), 138.5, 130.2, 129.3, 129.1, 128.7, 128.6, 126.6, 126.1, 122.5, 88.9 (d, J = 18.0 Hz), 85.6 (d, J = 183.5 Hz), 42.8 (d, J = 3.6 Hz), 21.5. 19F NMR (470 MHz, CDCl3) δ = −221.1 (t, J = 47.6 Hz, 1F). IR (neat): 2955, 1600, 1487, 1447, 1364, 1011, 922 cm−1. HRMS (ESI) m/z calcd. for C17H17FNO [M + H+]: 270.1289, found: 270.1286. 5-(3-Chlorophenyl)-5-(fluoromethyl)-3-phenylisoxazoline (3e). Colorless oil (54%, 15.6 mg). [α]27D = 33.3 (c = 0.19, CHCl3). The ee value (77% ee) was determined by HPLC analysis using a chiralpack IG-3 (n-hexane/i-PrOH = 80:20, flow rate = 1.0 mL/min, t(minor) = 8.8 min, t(major) = 10.2 min). 1H NMR (500 MHz, CDCl3) δ = 7.68–7.66 (m, 2H), 7.53 (s, 1H), 7.41–7.39 (m, 4H), 7.36–7.31 (m, 2H), 4.62 (dd, J = 10.0, 47.0 Hz, 1H), 4.56 (dd, J = 10.0, 47.0 Hz, 1H), 3.88 (d, J = 16.6 Hz, 1H), 3.50 (dd, J = 2.3, 16.6 Hz, 1H). 13C NMR (125 MHz, CDCl3) δ = 156.2, 142.3 (d, J = 2.4 Hz), 134.8, 130.4, 130.1, 128.9, 128.8, 128.6, 126.7, 125.9, 123.7, 88.3 (d, J = 19.2 Hz), 85.1 (d, J = 183.5 Hz), 43.1 (d, J = 3.6 Hz). 19F NMR (470 MHz, CDCl3) δ = −221.6 (t, J = 47.0 Hz, 1F). IR (neat): 2940, 1597, 1572, 1447, 1358, 1034, 995, 910 cm−1. HRMS (ESI) m/z calcd. for C16H14ClFNO [M + H+]: 290.0742, found: 290.0743. 5-(Fluoromethyl)-5-(4-fluorophenyl)-3-phenylisoxazoline (3f). Colorless solid (54%, 14.8 mg). [α]28D = 27.6 (c = 0.40, CHCl3). The ee value (73% ee) was determined by HPLC analysis using a chiralpack IG-3 (n-hexane/i-PrOH = 80:20, flow rate = 1.0 mL/min, t(minor) = 10.1 min, t(major) = 17.1 min). 1H NMR (500 MHz, CDCl3) δ = 7.68–7.66 (m, 2H), 7.51–7.48 (m, 2H), 7.42–7.38 (m, 3H), 7.11–7.08 (m, 2H), 4.61 (dd, J = 9.7, 47.5 Hz, 1H), 4.57 (dd, J = 9.7, 47.5 Hz, 1H), 3.88 (d, J = 16.6 Hz, 1H), 3.49 (dd, J = 2.3, 16.6 Hz, 1H). 13C NMR (125 MHz, CDCl3) δ = 162.6 (d, J = 247.1 Hz), 156.2, 136.0 (t, J = 3.6 Hz), 130.4, 129.1, 128.8, 127.4 (d, J = 8.4 Hz), 126.7, 115.7 (d, J = 21.6 Hz), 88.4 (d, J = 19.2 Hz), 85.3 (d, J = 183.5 Hz), 43.1 (d, J = 3.6 Hz). 19F NMR (470 MHz, CDCl3) δ = −113.5–−113.6 (m, 1F), −221.1 (t, J = 47.5 Hz, 1F). IR (neat): 1601, 1508, 1447, 1360, 1221, 1159, 1028, 918 cm−1. HRMS (ESI) m/z calcd. for C16H14F2NO [M + H+]: 274.1038, found: 274.1034. 5-Cyclohexyl-5-(fluoromethyl)-3-phenylisoxazoline (3g). Colorless oil (12%, 3.1 mg). [α]29D = 45.8 (c = 0.34, CHCl3). The ee value (65% ee) was determined by HPLC analysis using a chiralpack IG-3 (n-hexane/i-PrOH = 80:20, flow rate = 1.0 mL/min, t(minor) = 8.2 min, t(minor) = 9.2 min). 1H NMR (500 MHz, CDCl3) δ = 7.68–7.66 (m, 2H), 7.41–7.39 (m, 3H), 4.53 (dd, J = 9.7, 47.0 Hz, 1H), 4.49 (dd, J = 9.7, 47.0 Hz, 1H), 3.22 (d, J = 1.7 Hz, 2H), 1.82–1.78 (m, 5H), 1.71–1.69 (m, 1H), 1.32–1.05 (m, 5H). 13C NMR (125 MHz, CDCl3) δ = 155.7, 130.0, 129.6, 128.7, 126.5, 90.2 (d, J = 16.8 Hz), 84.2 (d, J = 177.5 Hz), 42.6 (d, J = 2.4 Hz), 37.9 (d, J = 6.0 Hz), 27.2, 26.5, 26.2, 26.1, 26.1. 19F NMR (470 MHz, CDCl3) δ = −229.6 (t, J = 47.0 Hz, 1F). IR (neat): 2922, 1595, 1447, 1360, 1009, 926 cm−1. HRMS (ESI) m/z calcd. for C16H21FNO [M + H+]: 262.1602, found: 262.1609. 3-(4-Bromophenyl)-5-(fluoromethyl)-5-phenylisoxazoline (3h). Colorless solid (37%, 12.4 mg). [α]28D = 22.5 (c = 0.39, CHCl3). The ee value (56% ee) was determined by HPLC analysis using a chiralpack IG-3 (n-hexane/i-PrOH = 80:20, flow rate = 1.0 mL/min, t(minor) = 12.9 min, t(major) = 20.4 min). 1H NMR (500 MHz, CDCl3) δ = 7.55–7.49 (m, 6H), 7.43–7.40 (m, 2H), 7.36–7.33 (m, 1H), 4.63 (dd, J = 10.3, 47.1 Hz, 1H), 4.59 (dd, J = 10.3, 47.1 Hz, 1H), 3.86 (d, J = 16.6 Hz, 1H), 3.50 (dd, J = 2.3, 16.6 Hz, 1H). 13C NMR (125 MHz, CDCl3) δ = 155.3, 139.8 (d, J = 4.8 Hz), 131.9, 128.8, 128.5, 128.2, 128.1, 125.4, 124.5, 89.3 (d, J = 18.0 Hz), 85.5 (d, J = 184.7 Hz), 42.6 (d, J = 3.6 Hz). 19F NMR (470 MHz, CDCl3) δ = −221.2 (t, J = 47.1 Hz, 1F). IR (neat): 2951, 1589, 1489, 1447, 1396, 1356, 1246, 989 cm−1. HRMS (ESI) m/z calcd. for C16H14BrFNO [M + H+]: 334.0237, found: 334.0237. 3-(3-Chlorophenyl)-5-(fluoromethyl)-5-phenylisoxazoline (3i). Colorless oil (58%, 16.8 mg). [α]28D = 43.5 (c = 0.30, CHCl3). The ee value (79% ee) was determined by HPLC analysis using a chiralpack IG-3 (n-hexane/i-PrOH = 80:20, flow rate = 1.0 mL/min, t(minor) = 8.1 min, t(major) =9.7 min). 1H NMR (500 MHz, CDCl3) δ = 7.66 (s, 1H), 7.57 (d, J = 7.5 Hz, 1H), 7.50 (d, J = 8.0 Hz, 2H), 7.43–7.40 (m, 2H), 7.38–7.31 (m, 3H), 4.64 (dd, J = 10.3, 47.1 Hz, 1H), 4.60 (dd, J = 10.3, 47.1 Hz, 1H), 3.87 (d, J = 16.6 Hz, 1H), 3.51 (dd, J = 2.3, 16.6 Hz, 1H). 13C NMR (125 MHz, CDCl3) δ = 155.2, 139.7 (d, J = 3.6 Hz), 134.7, 131.0, 130.2, 130.0, 128.8, 128.5, 126.7, 125.4, 124.7, 89.4 (d, J = 18.0 Hz), 85.5 (d, J = 184.7 Hz), 42.5 (d, J = 3.6 Hz). 19F NMR (470 MHz, CDCl3) δ = −221.2 (t, J = 47.1 Hz). IR (neat): 3063, 2947, 1595, 1560, 1429, 1344, 1028, 918 cm−1. HRMS (ESI) m/z calcd. for C16H14ClFNO [M + H+]: 290.0742, found: 290.0724. 5-(fluoromethyl)-5-phenyl-3-(3-thiophen-2-yl)isoxazoline (3j). Colorless solid (69%, 18.0 mg). [α]28D = 14.3 (c = 0.25, CHCl3). The ee value (84% ee) was determined by HPLC analysis using a chiralpack IG-3 (n-hexane/i-PrOH = 80:20, flow rate = 1.0 mL/min, t(minor) = 11.8 min, t(major) = 21.6 min). 1H NMR (500 MHz, CDCl3) δ = 7.52–7.50 (m, 2H), 7.43–7.38 (m, 3H), 7.36–7.33 (m, 1H), 7.21–7.20 (m, 1H), 7.06–7.04 (m, 1H), 4.63 (dd, J = 10.3, 47.5 Hz, 1H), 4.59 (dd, J = 10.3, 47.5 Hz, 1H), 3.90 (d, J = 16.2 Hz, 1H), 3.53 (dd, J = 2.6, 16.2 Hz, 1H). 13C NMR (125 MHz, CDCl3) δ = 152.0, 139.8 (d, J = 3.6 Hz), 131.7, 128.8, 128.5, 128.5, 128.4, 127.3, 125.5, 89.1 (d, J = 18.1 Hz), 85.3 (d, J = 183.5 Hz), 43.6 (d, J = 3.6 Hz). 19F NMR (470 MHz, CDCl3) δ = −221.1 (t, J = 47.5 Hz). IR (neat): 3084, 2943, 1600, 1491, 1437, 1024, 982, 907 cm−1. HRMS (ESI) m/z calcd. for C14H13FNOS [M + H+]: 262.0696, found: 262.0695.

4. Conclusions

In this paper, we have demonstrated the enantioselective 5-exo-fluorocyclization of ene-oximes using the linked-binaphthyl dicarboxylic acid precatalyst 1. The corresponding fluorinated isoxazolines were obtained with up to 84% ee, and the stereochemistry of the major isomers were determined to be S after transformation to known isoxazoline 8a with an iodomethyl unit. A control experiment revealed that hydrogen bond interaction of the oxime group is extremely important for the reaction acceleration and the enantioselectivity control. Further applications of the present fluorinating system are underway in our laboratory.
  30 in total

1.  Design and synthesis of isoxazoline derivatives as factor Xa inhibitors. 2.

Authors:  M L Quan; C D Ellis; A Y Liauw; R S Alexander; R M Knabb; G Lam; M R Wright; P C Wong; R R Wexler
Journal:  J Med Chem       Date:  1999-07-29       Impact factor: 7.446

2.  Asymmetric electrophilic fluorination using an anionic chiral phase-transfer catalyst.

Authors:  Vivek Rauniyar; Aaron D Lackner; Gregory L Hamilton; F Dean Toste
Journal:  Science       Date:  2011-12-23       Impact factor: 47.728

3.  Cinchona alkaloid catalyzed enantioselective fluorination of allyl silanes, silyl enol ethers, and oxindoles.

Authors:  Takehisa Ishimaru; Norio Shibata; Takao Horikawa; Naomi Yasuda; Shuichi Nakamura; Takeshi Toru; Motoo Shiro
Journal:  Angew Chem Int Ed Engl       Date:  2008       Impact factor: 15.336

4.  Dianionic Phase-Transfer Catalyst for Asymmetric Fluoro-cyclization.

Authors:  Hiromichi Egami; Tomoki Niwa; Hitomi Sato; Ryo Hotta; Daiki Rouno; Yuji Kawato; Yoshitaka Hamashima
Journal:  J Am Chem Soc       Date:  2018-02-12       Impact factor: 15.419

5.  Asymmetric fluorocyclizations of alkenes.

Authors:  Jamie R Wolstenhulme; Véronique Gouverneur
Journal:  Acc Chem Res       Date:  2014-11-07       Impact factor: 22.384

Review 6.  Applications of Fluorine in Medicinal Chemistry.

Authors:  Eric P Gillis; Kyle J Eastman; Matthew D Hill; David J Donnelly; Nicholas A Meanwell
Journal:  J Med Chem       Date:  2015-07-22       Impact factor: 7.446

Review 7.  Fluorine in pharmaceutical industry: fluorine-containing drugs introduced to the market in the last decade (2001-2011).

Authors:  Jiang Wang; María Sánchez-Roselló; José Luis Aceña; Carlos del Pozo; Alexander E Sorochinsky; Santos Fustero; Vadim A Soloshonok; Hong Liu
Journal:  Chem Rev       Date:  2013-12-03       Impact factor: 60.622

8.  Asymmetric Fluorolactonization with a Bifunctional Hydroxyl Carboxylate Catalyst.

Authors:  Hiromichi Egami; Junshi Asada; Kentaro Sato; Daisuke Hashizume; Yuji Kawato; Yoshitaka Hamashima
Journal:  J Am Chem Soc       Date:  2015-08-10       Impact factor: 15.419

9.  Catalytic Diastereo- and Enantioselective Fluoroamination of Alkenes.

Authors:  Katrina M Mennie; Steven M Banik; Elaine C Reichert; Eric N Jacobsen
Journal:  J Am Chem Soc       Date:  2018-03-29       Impact factor: 15.419

10.  Discovery of an orally bioavailable isoxazoline benzoxaborole (AN8030) as a long acting animal ectoparasiticide.

Authors:  Yong-Kang Zhang; Jacob J Plattner; Eric E Easom; Yasheen Zhou; Tsutomu Akama; Wei Bu; W Hunter White; Jean M Defauw; Joseph R Winkle; Terry W Balko; Shenghai Guo; Jian Xue; Jianxin Cao; Wuxin Zou
Journal:  Bioorg Med Chem Lett       Date:  2015-10-23       Impact factor: 2.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.